For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251212:nRSL4437La&default-theme=true
RNS Number : 4437L Brave Bison Group PLC 12 December 2025
Brave Bison Group plc
("Brave Bison" or the "Company", together with its subsidiaries "the Group")
Exercise of Options, Issue of Equity and Total Voting Rights
Brave Bison, the next-generation marketing and technology partner for global
brands, announces that on 10 December 2025 certain employees of the Group
exercised option rights over an aggregate of 202,451 ordinary shares of 2
pence each ("Ordinary Shares" and the "Options").
As a result, application will be made for a total of 202,451 new Ordinary
Shares to be admitted to trading on AIM ("Admission"). Admission is expected
to occur at 8.00 a.m. on 18 December 2025 and the new Ordinary Shares will, on
issue, rank pari passu in all respects with the Company's existing Ordinary
Shares.
On Admission, the Company will have a total of 102,474,298 Ordinary Shares in
issue. No Ordinary Shares are held in treasury. The figure of 102,474,298 may
be used by the Company's shareholders as the denominator in the calculations
by which they will determine if they are required to notify their interest in,
or a change to their interest in, the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.
For further information please contact:
Brave Bison Group plc
Oliver Green, Chairman
via Cavendish
Theo Green, Chief Growth Officer
Philippa Norridge, Chief Financial Officer
Cavendish Capital Markets
Tel: +44 (0) 20 7220 0500
Nominated Adviser & Joint Broker
Ben Jeynes / Teddy Whiley / Elysia Bough - Corporate Finance
Michael Johnson / Sunila de Silva - ECM
Singer Capital Markets
Tel: +44 (0)
20 7496 3000
Joint Broker
Alex Hardwicke
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEFFMFLEEISEIE
Copyright 2019 Regulatory News Service, all rights reserved